Universidad Complutense de Madrid
E-Prints Complutense

Antileukotrienes Improve Naso-Ocular Symptoms and Biomarkers inPatients With NARES and Asthma

Impacto

Downloads

Downloads per month over past year

De Corso, Eugenio and Anzivino, Roberta and Galli, Jacopo and Baroni, Silvia and Di Nardo, Walter and De Vita, Carla and Salvati, Antonio and Autilio, Chiara and Settimi, Stefano and Mele, Dario and Paludetti, Gaetano and Mullol, Joaquin (2019) Antileukotrienes Improve Naso-Ocular Symptoms and Biomarkers inPatients With NARES and Asthma. Laryngoscope, 129 . pp. 551-557. ISSN 1531-4995

[img]
Preview
PDF
631kB

Official URL: https://onlinelibrary.wiley.com/doi/full/10.1002/lary.27576?af=R



Abstract

Objective: The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).Methods: We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in mono-therapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinor-rhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction,difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. Thefollowing clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), TotalSymptom Score of Patient-Reported Outcomes (TSS-PROs), and a Composite Symptoms Score (CSS). Patients were classified asresponders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkersin nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin-1 and eotaxin-2.Results: Aft er tre atment, s ig nificant reductions were observed for all the symptom scores. Forty-two of 78 patients were con-sidered responders. A significant reduction of eosinophils in nasal mucosa and of levels of eotaxin-1 and eotaxin-2 in nasal lavagewere observed after treatment in responder patients. Patients with asthma had an increased probability to be responders.Conclusion: NARES patients may benefit from treatment with montelukast. In particular, the presence of concomitantasthma may be predictive of a greater efficacy.


Item Type:Article
Uncontrolled Keywords:NARES, asthma, antileukotrienes, montelukast, eosinophils, eotaxin, precision medicine
Subjects:Medical sciences > Medicine > Allergy
Medical sciences > Biology > Biochemistry
Medical sciences > Pharmacy > Pharmacology
ID Code:57074
Deposited On:23 Sep 2019 17:50
Last Modified:23 Sep 2019 17:50

Origin of downloads

Repository Staff Only: item control page